ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide; ARB, angiotensin receptor blocker; ARN, angiotensin receptor­neprilysin; ARNi; Aß, amyloid beta; BNP, brain natriuretic peptide; BP, blood pressure; CSF, cerebrospinal fluid; EF, ejection fraction; FDA, U.S. Food and Drug Administration; GFR, glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NEP inhibitor; NT-proBNP, N-terminal pro­brain natriuretic peptide; NYHA, New York Heart Association; PDE, phosphodiesterase; RAAS, renin-angiotensin-aldosterone system; UACR, urinary albumin/creatine ratio; angiotensin receptor­neprilysin inhibitor; cGMP, cyclic guanosine monophosphate; eGFR, estimated glomerular filtration rate; heart failure; neprilysin; neprilysin inhibitor; sacubitril; sacubitril/valsartan